Noxxon and Roche develop Spiegelmers

Noxxon Pharma AG has entered into a research and development collaboration with Roche regarding the discovery and development of Spiegelmers for the treatment of inflammatory diseases. In the partnership, Noxxon will use its Spiegelmer technology to identify inhibitors against two contractually named protein targets. Roche will conduct all pre-clinical and clinical development as well as the worldwide commercialisation of products.

Under the terms of the agreement, Noxxon will receive an upfront fee and research compensation, as well as additional payments for the achievement of specified development events. In addition, Noxxon is eligible to collect royalties on the sale of commercialised products.

"This partnership is another endorsement of the Spiegelmer technology and an indicator of the growing enthusiasm in the potential of Spiegelmers for treating disease," commented Sven Klussmann, Noxxon's chief executive and chief scientific officer.

"Roche's R & D achievements and its partnering record in the last decades speak for themselves. We are excited to work with a company that not only possesses tremendous expertise in the area of inflammatory diseases, but understands the process of building successful long-term relationships with young innovative biotech enterprises such as our own."

Spiegelmers are synthetic mirror-image RNA molecules not found in nature. Thanks to their unique mirror image configuration, Spiegelmers are not subject to degradation by nucleuses.

By screening oligonucleotide libraries of unrivalled size containing over 1015 different compounds, Noxxon claims to identify Spiegelmers that bind and inhibit their target molecules with high specificity and affinity.

Print | Email | Discuss this article |

READERS' COMMENTS

View all comments (0)

Have your say

Click here to post a comment

Add your Comment All posts are sent to the administrator for review and are published only after approval. ArabianBusiness.com reserves the right to remove any comment at any time for any reason. Please keep your responses appropriate and on topic.
Name *
Remember me on this computer
Email *	(Your email address will not be published)
City
Country
Subject *
Comment *
Notify me of further comments
Security Code *
Please click post only once - your comment will not be published immediately.

MORE FROM ARABIANBUSINESS.COM